A panel of experts discusses current strategies used to stratify risk in patients with myelofibrosis and their preferences for sequencing therapy.
EP. 1: Pathophysiology of Myelofibrosis
The role of signaling pathways, mutations, and alterations in the development of myelofibrosis (MF), and characteristics that distinguish primary MF from secondary MF.
EP. 2: Symptom Assessments in Myelofibrosis
The most common symptoms that present in patients with newly diagnosed myelofibrosis and variables that factor into initial treatment decisions.
EP. 3: Risk Stratifying Patients With Myelofibrosis
Criteria used to risk stratify and classify patients with newly diagnosed myelofibrosis and establish treatment paradigms.
EP. 4: Treatment Planning and Myelofibrosis
Characteristics that contribute to treatment decisions for patients with newly diagnosed myelofibrosis
EP. 5: Stem Cell Transplants in Myelofibrosis
Best practices in determining eligibility and preparing patients with myelofibrosis for allogeneic stem cell transplantation.
EP. 6: Pharmacotherapy for Myelofibrosis
Circumstances for which hydroxyurea, ruxolitinib, or other therapy may be selected to treat newly diagnosed myelofibrosis.
EP. 7: Approaching a Case of Primary Myelofibrosis
Review of criteria used to assess and plan treatment for a 67-year-old patient with primary myelofibrosis.
EP. 8: Assessing Treatment Response in Myelofibrosis
Monitoring patient response to frontline therapy for myelofibrosis, and circumstances for which a change in therapy may be appropriate.
EP. 9: Second-Line Treatment Options for Myelofibrosis
Second-line therapies for myelofibrosis that are available or in the pipeline for use.
EP. 10: Second-Line Therapy for High-Risk Primary Myelofibrosis
Second-line treatment considerations for a 75-year-old man with high-risk primary myelofibrosis who was previously treated with ruxolitinib.
EP. 11: Individualizing Therapy for Patients With Myelofibrosis
Clinical pearls for planning and sequencing therapy for patients with myelofibrosis.
EP. 12: Optimizing Therapy for Patients With Myelofibrosis
Responses to questions by community hematologists/oncologists regarding optimal ways to diagnose and manage patients with myelofibrosis.
EP. 13: Advances in the Treatment of Myelofibrosis
John Mascarenhas, MD, hosts a panel of experts who discusses current strategies used to stratify risk patients with myelofibrosis and their preferences for sequencing therapy.
2 Clarke Drive Cranbury, NJ 08512